Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 5/20 | 0.68 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.67 |
| ▸ | NPY1R | P25929 | 1/20 | 0.66 |
| ▸ | NPY2R | P49146 | 1/20 | 0.66 |
| ▸ | NPY4R | P50391 | 1/20 | 0.66 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.66 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.65 |
| ▸ | GLP1R | P43220 | 3/20 | 0.65 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.64 |
| ▸ | TFPI | P10646 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dynorphin A (1-17) SCHEMBL31331988 | 0.98 | NPY1R (0.68) | CXCR4KEAP1NPY1RNPY2RNPY4R | |
| Dynorphin A (1-17) SCHEMBL30248363 | 0.98 | NPY1R (0.68) | CXCR4KEAP1NPY1RNPY2RNPY4R | |
| SCHEMBL30439395 | 0.93 | OPRD1 (0.67) | CXCR4NPY1RNPY2RNPY4RNPY5R | |
| Dynorphin A (1-17) SCHEMBL29358748 | 0.91 | OPRD1 (0.70) | OPRD1 | |
| Dynorphin A (1-17) SCHEMBL29599476 | 0.91 | OPRD1 (0.70) | OPRD1 | |
| SCHEMBL30658277 | 0.90 | NPY2R (0.75) | CXCR4NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL30775448 | 0.90 | IL23R (0.68) | CXCR4KEAP1IL23RGLP1R | |
| SCHEMBL30404538 | 0.90 | KEAP1 (0.65) | CXCR4KEAP1NPY1RNPY2RNPY4R | |
| SCHEMBL30658215 | 0.89 | NPY1R (0.72) | CXCR4NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL29461541 | 0.89 | NPY1R (0.70) | CXCR4NPY1RNPY2RNPY4RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590131-B2 | Antimicrobial peptides with alpha-core helices | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER (US) | 2026-03-31 | — | — | US | disclosed |
| EP-3621632-B1 | ANTIMICROBIAL PEPTIDES WITH ALPHA-CORE HELICES | LOS ANGELES BIOMEDICAL RES INST HARBOR UCLA MEDICAL CT (US) | 2025-08-13 | — | — | EP | disclosed |
| US-20240279292-A1 | ANTIMICROBIAL PEPTIDES WITH ALPHA-CORE HELICES | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 2024-08-22 | — | — | US | disclosed |
| US-11987607-B2 | Antimicrobial peptides with alpha-core helices | The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center (US) | 2024-05-21 | — | — | US | disclosed |
| US-20230227516-A1 | ANTIMICROBIAL PEPTIDES WITH ALPHA-CORE HELICES | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12590131-B2 | Antimicrobial peptides with alpha-core helices | VIP, HAMP, HM13 | CXCR4 2703/4885KEAP1 3922/4885NPY1R 643/4885 |
| US-11987607-B2 | Antimicrobial peptides with alpha-core helices | VIP, NGLY1, SPPL2B | CXCR4 2254/4885KEAP1 2945/4885NPY1R 2087/4885 |
| US-20240279292-A1 | ANTIMICROBIAL PEPTIDES WITH ALPHA-CORE HELICES | VIP, NGLY1, SPPL2B | CXCR4 2254/4885KEAP1 2945/4885NPY1R 2087/4885 |
| US-20230227516-A1 | ANTIMICROBIAL PEPTIDES WITH ALPHA-CORE HELICES | VIP, NGLY1, SPPL2B | CXCR4 2254/4885KEAP1 2945/4885NPY1R 2087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.